ACRO BIOMEDICAL CO., LTD. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ACRO BIOMEDICAL CO., LTD. (ACBM) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$450 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- ACRO BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$225.00.
- ACRO BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$225.00.
- ACRO BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$225.00.
- ACRO BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$5.53K, a 102.11% decline year-over-year.
- ACRO BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $3.62K, a 3522.00% increase from fiscal 2024.
- ACRO BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $100.00.
- ACRO BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$5.48K.
- ACRO BIOMEDICAL CO., LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$89.40K, a 215.91% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$450.00 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$225.00 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $3.62K 10-K · filed 2026-02-11 | |||
| 2025-09-30 | $3.85K 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | -$450.00 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$225.00 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | $100.00 10-K · filed 2026-02-11 | |||
| 2024-09-30 | $325.00 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $550.00 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | -$225.00 10-Q · filed 2025-07-24 | |||
| 2023-12-31 | -$5.48K 10-K · filed 2025-07-24 | |||
| 2023-09-30 | -$2.58K 10-Q · filed 2025-07-23 | |||
| 2023-06-30 | -$3.17K 10-Q · filed 2025-07-23 | |||
| 2023-03-31 | -$5.53K 10-Q · filed 2025-07-22 | |||
| 2022-12-31 | -$89.40K 10-K · filed 2025-07-18 | |||
| 2022-09-30 | -$79.06K 10-Q · filed 2025-07-11 | |||
| 2022-06-30 | -$83.14K 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $262.42K 10-Q · filed 2023-08-02 | |||
| 2021-12-31 | $77.13K 10-K · filed 2023-07-21 | |||
| 2021-09-30 | $136.54K 10-Q · filed 2022-11-21 | |||
| 2021-06-30 | $197.37K 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | $6.24K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $17.21K 10-K · filed 2022-04-15 |